ADPT Stock Overview
A commercial-stage company, develops an immune medicine platform for the diagnosis and treatment of various diseases.
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 1/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
Adaptive Biotechnologies Corporation Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$3.46 |
| 52 Week High | US$9.08 |
| 52 Week Low | US$2.28 |
| Beta | 1.27 |
| 1 Month Change | 37.85% |
| 3 Month Change | -10.82% |
| 1 Year Change | -50.29% |
| 3 Year Change | -90.67% |
| 5 Year Change | n/a |
| Change since IPO | -91.41% |
Recent News & Updates
Recent updates
Is Adaptive Biotechnologies (NASDAQ:ADPT) Using Too Much Debt?
May 08
It's Down 26% But Adaptive Biotechnologies Corporation (NASDAQ:ADPT) Could Be Riskier Than It Looks
Apr 03Adaptive Biotechnologies: A Post Earnings Assessment
Feb 25Analysts Just Shaved Their Adaptive Biotechnologies Corporation (NASDAQ:ADPT) Forecasts Dramatically
Feb 17Not Many Are Piling Into Adaptive Biotechnologies Corporation (NASDAQ:ADPT) Stock Yet As It Plummets 25%
Feb 01Analysts Are More Bearish On Adaptive Biotechnologies Corporation (NASDAQ:ADPT) Than They Used To Be
Nov 17Is Adaptive Biotechnologies (NASDAQ:ADPT) A Risky Investment?
Oct 13Is Adaptive Biotechnologies (NASDAQ:ADPT) A Risky Investment?
Jul 06Investors Give Adaptive Biotechnologies Corporation (NASDAQ:ADPT) Shares A 26% Hiding
May 05We're Hopeful That Adaptive Biotechnologies (NASDAQ:ADPT) Will Use Its Cash Wisely
Apr 15Adaptive Biotechnologies (NASDAQ:ADPT) Is In A Good Position To Deliver On Growth Plans
Dec 13Adaptive Biotechnologies, Epic team up to integrate clonoSEQ test in electronic record system
Oct 11Adaptive Biotechnologies announces $250M non-dilutive royalty financing
Sep 12We're Not Very Worried About Adaptive Biotechnologies' (NASDAQ:ADPT) Cash Burn Rate
Aug 14Companies Like Adaptive Biotechnologies (NASDAQ:ADPT) Are In A Position To Invest In Growth
Apr 29Adaptive Biotechnologies: Good Buy For Long-Term Investors
Apr 15Are Investors Undervaluing Adaptive Biotechnologies Corporation (NASDAQ:ADPT) By 22%?
Feb 26We Think Adaptive Biotechnologies (NASDAQ:ADPT) Can Afford To Drive Business Growth
Jan 09Our First Assessment On Adaptive Biotechnologies
Dec 16Adaptive Biotechnologies (NASDAQ:ADPT) Is In A Good Position To Deliver On Growth Plans
Sep 26Shareholder Returns
| ADPT | US Life Sciences | US Market | |
|---|---|---|---|
| 7D | -11.3% | -0.1% | 1.2% |
| 1Y | -50.3% | 8.0% | 27.7% |
Return vs Industry: ADPT underperformed the US Life Sciences industry which returned 8% over the past year.
Return vs Market: ADPT underperformed the US Market which returned 27.7% over the past year.
Price Volatility
| ADPT volatility | |
|---|---|
| ADPT Average Weekly Movement | 11.8% |
| Life Sciences Industry Average Movement | 6.8% |
| Market Average Movement | 5.9% |
| 10% most volatile stocks in US Market | 16.2% |
| 10% least volatile stocks in US Market | 2.8% |
Stable Share Price: ADPT's share price has been volatile over the past 3 months.
Volatility Over Time: ADPT's weekly volatility (12%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2009 | 709 | Chad Robins | www.adaptivebiotech.com |
Adaptive Biotechnologies Corporation, a commercial-stage company, develops an immune medicine platform for the diagnosis and treatment of various diseases. The company offers immunosequencing platform which combines a suite of proprietary chemistry, computational biology, and machine learning to generate clinical immunomics data to decode the adaptive immune system. It also provides clonoSEQ diagnostic test which detects and monitors the remaining number of cancer cells that are present in a patient’s body during and after treatment, known as Minimal Residual Disease (MRD).
Adaptive Biotechnologies Corporation Fundamentals Summary
| ADPT fundamental statistics | |
|---|---|
| Market cap | US$514.32m |
| Earnings (TTM) | -US$215.06m |
| Revenue (TTM) | US$174.50m |
2.9x
P/S Ratio-2.4x
P/E RatioIs ADPT overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| ADPT income statement (TTM) | |
|---|---|
| Revenue | US$174.50m |
| Cost of Revenue | US$95.52m |
| Gross Profit | US$78.98m |
| Other Expenses | US$294.04m |
| Earnings | -US$215.06m |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -1.46 |
| Gross Margin | 45.26% |
| Net Profit Margin | -123.24% |
| Debt/Equity Ratio | 47.9% |
How did ADPT perform over the long term?
See historical performance and comparison